Megan Washington
A5103275666- Chromatin Remodeling and Cancer
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Multiple Myeloma Research and Treatments
- Mechanisms of cancer metastasis
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Veterinary Oncology Research
- vaccines and immunoinformatics approaches
- Cutaneous Melanoma Detection and Management
- Chromosomal and Genetic Variations
- Infectious Diseases and Mycology
Translational Genomics Research Institute
2017-2024
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The Myeloma Research Foundation's Relating Clinical Outcomes in Personal Assessment Genetic Profile study ( NCT01454297 ) longitudinal, observational clinical newly diagnosed patients with multiple (n = 1,143) where samples using whole-genome sequencing, whole-exome sequencing...
Multiple Myeloma (MM) is a plasma cell malignancy with significantly greater incidence and mortality rates among African Americans (AA) compared to Caucasians (CA). The overall goal of this study elucidate differences in molecular alterations MM as function self-reported race genetic ancestry. Our utilized somatic whole exome, RNA-sequencing, correlated clinical data from 718 patients the Research Foundation CoMMpass Interim Analysis 9. Somatic mutational analyses based upon corrected for...
Canine malignant melanoma, a significant cause of mortality in domestic dogs, is powerful comparative model for human but little known about its genetic etiology. We mapped the genomic landscape canine melanoma through multi-platform analysis 37 tumors (31 mucosal, 3 acral, 2 cutaneous, and 1 uveal) 17 matching constitutional samples including long- short-insert whole genome sequencing, RNA array hybridization, single nucleotide polymorphism array, targeted Sanger sequencing analyses....
Abstract Purpose: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive ovarian cancer in young women that universally driven by loss SWI/SNF ATPase subunits SMARCA4 and SMARCA2. A great need exists for effective targeted therapies SCCOHT. Experimental Design: To identify underlying therapeutic vulnerabilities SCCOHT, we conducted high-throughput siRNA drug screens. Complementary proteomics approaches profiled kinases inhibited ponatinib. Ponatinib was tested...
Abstract Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The MMRF CoMMpass study longitudinal, observational clinical newly diagnosed multiple patients where samples using whole genome, exome, RNA sequencing at diagnosis progression, data collected every three months. Analyses the baseline cohort identified genes that target...
Structured Abstract Purpose: Subunits of the SWI/SNF chromatin-remodeling complex are tumor suppressors inactivated in ∼20% all cancers. Yet, few targeted treatments for SWI/SNF-mutant cancers exist. Small cell carcinoma ovary, hypercalcemic type (SCCOHT) is a rare, aggressive ovarian cancer young women that universally driven by loss ATPase subunits, SMARCA4 and SMARCA2. Given poor two-year survival rates these women, great need exists effective therapies. Experimental Design: To identify...
<p>Supplemental Materials and Methods</p>
<p>List of high-throughput drug screen hits.</p>
<p>MIB-MS data.</p>
<p>List of validated siRNA screen hits.</p>
<p>Summary of hits from ponatinib analyses and target expression.</p>
<p>Supplemental Table 5. SCCOHT-1 ABPP data; Supplemental 6. BIN67 data.</p>
<p>IC50 summary of validated drug hits in SCCOHT cell lines.</p>
<p>Supplemental Figure 1. COV434-pIND20-Brg1 SMARCA4 induction optimization; Supplemental 2. Kinase hits from siRNA screen mapped to kinome dendrogram; 3. ClueGo analysis of validated hits.</p>
<div>Abstract<p><b>Purpose:</b> Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive ovarian cancer in young women that universally driven by loss SWI/SNF ATPase subunits SMARCA4 and SMARCA2. A great need exists for effective targeted therapies SCCOHT.</p><p><b>Experimental Design:</b> To identify underlying therapeutic vulnerabilities SCCOHT, we conducted high-throughput siRNA drug screens. Complementary...
<div>Abstract<p><b>Purpose:</b> Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive ovarian cancer in young women that universally driven by loss SWI/SNF ATPase subunits SMARCA4 and SMARCA2. A great need exists for effective targeted therapies SCCOHT.</p><p><b>Experimental Design:</b> To identify underlying therapeutic vulnerabilities SCCOHT, we conducted high-throughput siRNA drug screens. Complementary...
<p>MIB-MS data.</p>
<p>Summary of hits from ponatinib analyses and target expression.</p>
<p>IC50 summary of validated drug hits in SCCOHT cell lines.</p>
<p>Supplemental Table 5. SCCOHT-1 ABPP data; Supplemental 6. BIN67 data.</p>
<p>List of high-throughput drug screen hits.</p>
<p>Supplemental Materials and Methods</p>
<p>List of validated siRNA screen hits.</p>
<p>Supplemental Figure 1. COV434-pIND20-Brg1 SMARCA4 induction optimization; Supplemental 2. Kinase hits from siRNA screen mapped to kinome dendrogram; 3. ClueGo analysis of validated hits.</p>